ClinicalTrials.gg
CompletedNCT01466985Updated Feb 15, 2019Results posted

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

A Phase 1 interventional study of Doravirine and Placebo in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a study to evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of doravirine (MK-1439) as monotherapy in antiretroviral therapy (ART)-naïve, HIV-1-infected participants.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of -1-infection ≥3 months prior to screening
  • Participants with female partner(s) of must agree to use a medically acceptable method of during the study and for 90 days after the last dose of study drug
  • (BMI) ≤35 kg/m\^2
  • Other than HIV infection, participant's baseline health is judged to be stable
  • No abnormality on (ECG)
  • Participant is ART-naïve (defined as having never received any antiretroviral agent or ≤30 consecutive days of an antiretroviral agent (excluding an Non-Nucleoside Reverse Transcriptase Inhibitor [NNRTI]) or ≤60 consecutive days of combination ART not including an NNRTI)
  • Participant is willing to receive no other ART for the duration of the treatment phase of this study.

Exclusion criteria

Exclusion Criteria:

  • History of stroke, chronic seizures, or major neurological disorder
  • History of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological (outside of -1 infection), renal, respiratory, or genitourinary abnormalities or diseases
  • History of clinically significant neoplastic disease
  • Participant has used any immune therapy agents or therapy within 1 month prior to treatment in this study
  • Participant has one or more pre-existing risk factors for Torsades de Pointes ( Functional Classification II through IV heart failure, familial long--syndrome, uncorrected hypokalemia, QTcF >470 msec)
  • Participant requires or is anticipated to require chronic daily prescription medications
  • Current (active) diagnosis of acute hepatitis due to any cause
  • History of chronic virus (HCV) unless there has been documented cure and/or patient with a positive serologic test for HCV has a negative HCV viral load.
  • Positive surface antigen
  • Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies (such as St. John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study, until the post-study visit
  • Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day
  • Participant consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day
  • Participant is an excessive smoker (i.e., more than 10 cigarettes/day) and is unwilling to restrict smoking to ≤10 cigarettes per day
  • Major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit
  • Participation in another study within 4 weeks prior to the prestudy (screening) visit
  • History of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
  • Current regular user (including use of any illicit drugs) or has a history of drug (including alcohol) abuse within approximately 1 year
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Panel A: Doravirine 25 mg or Placebo

    Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.

    Drug: Doravirine · Drug: Placebo

  • Experimental
    Panel B: Doravirine 200 mg or Placebo

    Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.

    Drug: Doravirine · Drug: Placebo

  • Experimental
    Panel C: Doravirine or Placebo

    Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.

    Drug: Doravirine · Drug: Placebo

Interventions

  • Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).

    Also known as: MK-1439

  • DrugPlacebo

    Placebo tablets once daily for 7 days.

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load

    The change from baseline to Day 7 in plasma HIV RNA viral load was determined for each arm. Results are expressed as change in HIV RNA log10 copies/mL after 7 daily doses of doravirine or placebo. It was hypothesized that at least 1 dose of doravirine would be superior to placebo as documented by the upper bound of the 90% confidence interval \<-1. Plasma HIV RNA levels were determined using the Abbott RealTime HIV assay which has a linear range from 40 to 10 million copies/mL.

    Time frame: Baseline and Day 7

Secondary outcomes

  1. Area Under the Plasma Concentration Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of Doravirine on Day 7

    The AUC0-24hr of doravirine on Day 7 was determined in the doravirine treatment arms.

    Time frame: Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7

  2. Maximum Plasma Concentration (Cmax) of Doravirine on Day 7

    The Cmax of doravirine on Day 7 was determined in the doravirine treatment arms.

    Time frame: Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7

  3. Plasma Concentration 24 Hours Postdose (C24hr) of Doravirine on Day 7

    The C24hr of doravirine on Day 7 was determined in the doravirine treatment arms.

    Time frame: 24 hours postdose on Day 7 (Day 8)

  4. Time to Maximum Plasma Concentration (Tmax) of Doravirine on Day 7

    The Tmax of doravirine on Day 7 was determined in the doravirine treatment arms.

    Time frame: Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7

07

Results

Posted Feb 15, 2019

Participant flow

Participants with human immunodeficiency virus type 1 (HIV-1) who were antiretroviral therapy (ART)-naïve were enrolled at a single study center in Germany.

Participant flow — Overall Study
MilestoneDoravirine 25 mgDoravirine 200 mgPlacebo
Started666
Completed666
Not completed000

Outcome measures

PrimaryPercentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load

The change from baseline to Day 7 in plasma HIV RNA viral load was determined for each arm. Results are expressed as change in HIV RNA log10 copies/mL after 7 daily doses of doravirine or placebo. It was hypothesized that at least 1 dose of doravirine would be superior to placebo as documented by the upper bound of the 90% confidence interval \<-1. Plasma HIV RNA levels were determined using the Abbott RealTime HIV assay which has a linear range from 40 to 10 million copies/mL.

Time frame:
Baseline and Day 7
Reported as:
Least squares mean · Percentage change
Percentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load
Percentage changeDoravirine 25 mgDoravirine 200 mgPlacebo
Percentage Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load-1.52 (-1.71 to -1.32)-1.41 (-1.61 to -1.21)-0.15 (-0.35 to 0.06)
Statistical analysis
  • Doravirine 25 mg vs Placebo · ANCOVA · p = <0.001 · Least squares (ls) mean difference: -1.37 · 90% CI -1.60 to -1.02
  • Doravirine 200 mg vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -1.26 · 90% CI -1.51 to -1.02
SecondaryArea Under the Plasma Concentration Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of Doravirine on Day 7

The AUC0-24hr of doravirine on Day 7 was determined in the doravirine treatment arms.

Time frame:
Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7
Reported as:
Geometric mean · uM*hr
Area Under the Plasma Concentration Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of Doravirine on Day 7
uM*hrDoravirine 25 mgDoravirine 200 mg
Area Under the Plasma Concentration Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of Doravirine on Day 711.2 (9.35 to 13.4)62.2 (52.0 to 74.4)
SecondaryMaximum Plasma Concentration (Cmax) of Doravirine on Day 7

The Cmax of doravirine on Day 7 was determined in the doravirine treatment arms.

Time frame:
Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7
Reported as:
Geometric mean · nM
Maximum Plasma Concentration (Cmax) of Doravirine on Day 7
nMDoravirine 25 mgDoravirine 200 mg
Maximum Plasma Concentration (Cmax) of Doravirine on Day 7826 (727 to 938)4300 (3790 to 4890)
SecondaryPlasma Concentration 24 Hours Postdose (C24hr) of Doravirine on Day 7

The C24hr of doravirine on Day 7 was determined in the doravirine treatment arms.

Time frame:
24 hours postdose on Day 7 (Day 8)
Reported as:
Geometric mean · nM
Plasma Concentration 24 Hours Postdose (C24hr) of Doravirine on Day 7
nMDoravirine 25 mgDoravirine 200 mg
Plasma Concentration 24 Hours Postdose (C24hr) of Doravirine on Day 7251 (188 to 335)1540 (1150 to 2060)
SecondaryTime to Maximum Plasma Concentration (Tmax) of Doravirine on Day 7

The Tmax of doravirine on Day 7 was determined in the doravirine treatment arms.

Time frame:
Predose and 1, 2, 4, 6, 8, 10, 12 and 24 hours postdose on Day 7
Reported as:
Median · Hours
Time to Maximum Plasma Concentration (Tmax) of Doravirine on Day 7
HoursDoravirine 25 mgDoravirine 200 mg
Time to Maximum Plasma Concentration (Tmax) of Doravirine on Day 71.00 (1.00 to 2.00)2.00 (1.00 to 4.00)

Adverse events

Collected over Up to 14 days after the last dose of study drug (up to 21 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doravirine 25 mg0/6 (0%)0/6 (0%)3/6 (50%)
Doravirine 200 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Placebo0/6 (0%)0/6 (0%)3/6 (50%)
Poststudy0/18 (0%)1/18 (5.6%)1/18 (5.6%)
Most frequent serious events
Most frequent serious events
EventDoravirine 25 mgDoravirine 200 mgPlaceboPoststudy
Hepatic enzyme increasedInvestigations0/60/60/61/18
Most frequent other events
Showing 10 of 17
Most frequent other events
EventDoravirine 25 mgDoravirine 200 mgPlaceboPoststudy
DiarrhoeaGastrointestinal disorders1/62/60/60/18
HeadacheNervous system disorders0/62/62/60/18
PalpitationsCardiac disorders0/61/60/60/18
Abdominal painGastrointestinal disorders0/61/60/60/18
NauseaGastrointestinal disorders1/61/60/60/18
NasopharyngitisInfections and infestations0/60/61/60/18
Oral herpesInfections and infestations0/61/60/60/18
TonsilitisInfections and infestations0/60/61/60/18
Alanine aminotransferase increasedInvestigations1/60/60/60/18
Aspartate aminotransferase increasedInvestigations1/60/60/60/18

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Doravirine 25 mgDoravirine 200 mgPlaceboTotal
Mean36.7 ± 5.834.8 ± 8.426.8 ± 1.032.8 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Doravirine 25 mgDoravirine 200 mgPlaceboTotal
Female0000
Male66618
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Schurmann D, Sobotha C, Gilmartin J, Robberechts M, De Lepeleire I, Yee KL, Guo Y, Liu R, Wagner F, Wagner JA, Butterton JR, Anderson MS. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS. 2016 Jan 2;30(1):57-63. doi: 10.1097/QAD.0000000000000876. PubMed 26372481 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2011 to primary completion in Apr 2012, 5 months.

Results were first posted in Feb 2019, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2011
First posted
Nov 8, 2011
StartActual
Oct 21, 2011
Primary completionActual
Apr 10, 2012
CompletionActual
Apr 10, 2012
Results first posted
Feb 15, 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01466985
Responsible party
Sponsor
First posted
Nov 8, 2011
Start date
Oct 21, 2011
Primary completion
Apr 10, 2012
Completion
Apr 10, 2012
Results posted
Feb 15, 2019
Last update
Feb 15, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doravirine

Start the discussion